ArticleCell host & microbe2023
High-throughput identification of Toxoplasma gondii effector proteins that target host cell transcription.
Article in Cell host & microbe, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 15 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
15 citing papers in PubMed, 25 citations in OpenAlex.
- Article
- A Suite of EightbioRxiv : the preprint server for biology · 2026Article
- Toxoplasma effector TgROP1 establishes membrane contact sites with the endoplasmic reticulum during infection.Nature microbiology · 2025Article
- CRISPR-based genetic tools for the study of host-microbe interactions.Infection and immunity · 2025Review
- Targeted CRISPR screens reveal genes essential for Cryptosporidium survival in the host intestine.Nature communications · 2025Article
- Next generation genetic screens in kinetoplastids.Nucleic acids research · 2025Review
- GRA12 is a common virulence factor across Toxoplasma gondii strains and mouse subspecies.Nature communications · 2025Article
- Individually redundant effectors are collectively required for bacterial pathogen virulence.The ISME journal · 2025Article
- The importance of translational research in the study of ocular toxoplasmosis: insights from the 17th International Congress on Toxoplasmosis 2024.FEMS microbes · 2025Article
- Paracrine rescue of MYR1-deficienteLife · 2024Article
- Dissecting host-microbe interactions with modern functional genomics.Current opinion in microbiology · 2024Review
- Eimeria: Navigating complex intestinal ecosystems.PLoS pathogens · 2024Review
- CRISPR screens identify genes essential formBio · 2024Article
- Toxoplasma protein export and effector function.Nature microbiology · 2024Review
- mSphere of Influence: Systemic decoding gene function inmSphere · 2023Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors at 2 institutions in 3 countries.
Funding
Abstract
Intracellular pathogens and other endosymbionts reprogram host cell transcription to suppress immune responses and recalibrate biosynthetic pathways. This reprogramming is critical in determining the outcome of infection or colonization. We combine pooled CRISPR knockout screening with dual host-microbe single-cell RNA sequencing, a method we term dual perturb-seq, to identify the molecular mediators of these transcriptional interactions. Applying dual perturb-seq to the intracellular pathogen Toxoplasma gondii, we are able to identify previously uncharacterized effector proteins and directly infer their function from the transcriptomic data. We show that TgGRA59 contributes to the export of other effector proteins from the parasite into the host cell and identify an effector, TgSOS1, that is necessary for sustained host STAT6 signaling and thereby contributes to parasite immune evasion and persistence. Together, this work demonstrates a tool that can be broadly adapted to interrogate host-microbe transcriptional interactions and reveal mechanisms of infection and immune evasion.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.